Cancer Genetics and Epigenetics 2024, Vol.12, No.5, 234-253 http://medscipublisher.com/index.php/cge 253 Yin K., Xia X.L., Rui K., Wang T.T., and Wang S.J., 2020, Myeloid-derived suppressor cells: a new and pivotal player in colorectal cancer progression, Frontiers in Oncology, 10: 610104. https://doi.org/10.3389/fonc.2020.610104 PMID: 33384962 PMCID: PMC7770157 Yoo S.Y., Badrinath N., Jeong S.N., Woo H.Y., and Heo J., 2020, Overcoming tumor resistance to oncolyticvaccinia virus with Anti-PD-1-Based combination therapy by inducing antitumor immunity in the tumor microenvironment, Vaccines, 8(2): 321. https://doi.org/10.3390/vaccines8020321 PMID: 32575351 PMCID: PMC7350271 Yu Y., and Cui J.W., 2018, Present and future of cancer immunotherapy: a tumor microenvironmental perspective, Oncology Letters, 16(4): 4105-4113. https://doi.org/10.3892/ol.2018.9219 Yuan Y., Meric-Bernstam F., Chen K., and Yap T.A., 2022, Clinical and molecular characterization of pole mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers, JCO Precision Oncology, 6: e2100267. https://doi.org/10.1200/PO.21.00267 Zeng X.Z., Ward S.E., Zhou J.Y., and Cheng A.S.L., 2021, Liver immune microenvironment and metastasis from colorectal cancer-pathogenesis and therapeutic perspectives, Cancers, 13(10): 2418. https://doi.org/10.3390/cancers13102418 Zhao J., Chen Y., Ding Z.Y., and Liu J.Y., 2019, Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment, Frontiers in Pharmacology, 10: 1184. https://doi.org/10.3389/fphar.2019.01184 PMID: 31680963 PMCID: PMC6798079 Zhao Y.S., Deng, J., Rao S.F., Guo S.P., Shen, J., Du F.K., Wu X., Chen Y., Li M.X., Chen M.J., Li X.B., Li W.P., Gu L., Sun Y.H., Zhang Z., Wen Q.L., Xiao Z.G., and Li J., 2022, Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges, Cancers, 14(17): 4160. https://doi.org/10.3390/cancers14174160
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==